The impact of peptidase activity on clear cell renal cell carcinoma survival

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 12, 2012, Pages

  Larrinaga, Gorka ^a,d   Blanco, Lorena ^a,d   Sanz, Begoña ^a,d   Perez, Itxaro ^a,d   Gil, Javier ^a,d   Unda, Miguel ^b   Andrés, Leire ^c,d   Casis, Luis ^a   López, José I ^c,d  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

Author keywords

Bioactive peptides; Clear cell renal cell carcinoma; Peptidases; Prognosis; Proteases; Renal cancer; Survival

Indexed keywords

5 OXOPROLYL PEPTIDASE; AMINOPEPTIDASE B; ASPARTYL AMINOPEPTIDASE; CYSTYL AMINOPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; MATRIX METALLOPROTEINASE; MEMBRANE METALLOENDOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; PEPTIDASE; PROLYL ENDOPEPTIDASE; PUROMYCIN SENSITIVE AMINOPEPTIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CATALYSIS; CLEAR CELL CARCINOMA; ENZYME ACTIVITY; FEMALE; FLUOROMETRY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 84871305578     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00477.2012     Document Type: Article

References (65)

1. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 29: 1675-1684, 2008.
2. Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res 18: 1447-1456, 2012.
3. Balogh A, Cadel S, Foulon T, Picart R, Der Garabedian A, Rousselet A, Tougard C, Cohen P. Aminopeptidase B: a processing enzyme secreted and associated with the plasma membrane of rat pheochromocytoma (PC12) cells. J Cell Sci 111: 161-169, 1998.
4. Blanco L, Larrinaga G, Pérez I, López JI, Gil J, Agirregoitia E, Varona A. Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. Am J Physiol Renal Physiol 294: F850-F858, 2008.
5. Blanco L, Perez I, Sanz B, Gil J, López JI, Ugalde A, Varona A, Larrinaga G. Changes in cell-surface peptidase activity in papillary renal cell carcinoma. Anticancer Res 30: 1137-1141, 2010.
6. Borboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20: 161-168, 2010.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
8. Cadel S, Piesse C, Gouzy-Darmon C, Cohen P, Foulon T. Arginyl aminopeptidase. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum, 2004, p. 113-126.
9. Carl-McGrath S, Lendeckel U, Ebert M, Röcken C. Ectopeptidases in tumour biology: a review. Histol Histopathol 21: 1339-1353, 2006.
10. Che M, Grignon DJ. Handling and reporting of tumor-containing kidney specimens. Clin Lab Med 25: 417-432, 2005.
11. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624, 2003.
12. Cordero OJ, Ayude D, Nogueira M, Rodríguez-Berrocal FJ, Páez de la Cadena M. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 80: 1139-1146, 2000.
13. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 58: 1723-1747, 2009.
14. Deschamps L, Handra-Luca A, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J, Bedossa P, Couvelard A. CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Hum Pathol 37: 802-808, 2006.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual (7th ed.). New York: Springer, 2010.
16. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
17. Furhman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
18. Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med 2: 409-414, 1998.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100: 57-70, 2000.
20. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122: 376-386, 2002.
21. Ichinose Y, Genka K, Koike T, Kato H, Watanabe Y, Mori T, Iioka S, Sakuma A, Ohta M. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 95: 605-610, 2003.
22. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 9: 1503-1508, 2003.
23. Inamoto T, Yamochi T, Ohnuma K, Iwata S, Kina S, Inamoto S, Tachibana M, Katsuoka Y, Dang NH, Morimoto C. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res 12: 3470-3477, 2006.
24. Ino K, Shibata K, Kajiyama H, Kikkawa F, Mizutani S. Regulatory role of membrane-bound peptidases in the progression of gynecologic malignancies. Biol Chem 385: 683-690, 2004.
25. Kehlen A, Göhring B, Langner J, Riemann D. Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators. Clin Exp Immunol 111: 435-441, 1998.
26. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S. Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 1751: 45-51, 2005.
27. Larrinaga G, Lopez JI, Casis L, Blanco L, Gil J, Agirregoitia E, Varona A. Cystinyl aminopeptidase activity is decreased in renal cell carcinomas. Regul Pept 144: 56-61, 2007.
28. Larrinaga G, Perez I, Blanco L, López JI, Andrés L, Etxezarraga C, Santaolalla F, Zabala A, Varona A, Irazusta J. Increased prolyl endopeptidase activity in human neoplasia. Regul Pept 163: 102-106, 2010.
29. Larrinaga G, Pérez I, Sanz B, Blanco L, López JI, Cándenas ML, Pinto FM, Gil J, Irazusta J, Varona A. Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regul Pept 165: 218-223, 2010.
30. Lewis G, Maxwell AP. Early diagnosis improves survival in kidney cancer. Practitioner 256: 13-16, 2012.
31. López-Beltrán A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 49: 798-805, 2006.
32. Mantle D, Lauffart B, McDermott J, Gibson A. Characterization of aminopeptidases in human kidney soluble fraction. Clin Chim Acta 187: 105-113, 1990.
33. Martínez JM, Prieto I, Ramírez MJ, Cueva C, Alba F, Martínez M. Aminopeptidase activities in breast cancer tissue. Clin Chem 45: 1797-1802, 1999.
34. Masuda S, Hattori A, Matsumoto H, Miyazawa S, Natori Y, Mizutani Tsujimoto MS. Involvement of the V2 receptor in vasopressin-stimulated translocation of placental leucine aminopeptidase/oxytocinase in renal cells. Eur J Biochem 270: 1988-1994, 2003.
35. Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M, Koga S, Kanetake H. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol 52: 791-797, 2007.
36. Mourad WF, Dutcher J, Ennis RD. State-of-the art management of renal cell carcinoma. Am J Clin Oncol (Epub ahead of print).
37. Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M. Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res 11: 8674-8679, 2005.
38. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, Bander NH, Albino AP, Reuter VE. Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncol 13: 261-267, 1998.
39. Olivo RA, Teixeira CF, Silveira PF. Representative aminopeptidases and prolyl endopeptidase from murine macrophages: comparative activity levels in resident and elicited cells. Biochem Pharmacol 69: 1441-1450, 2005.
40. Pérez I, Varona A, Blanco L, Gil J, Santaolalla F, Zabala A, Ibarguren AM, Irazusta J, Larrinaga G. Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma. Head Neck 31: 1335-1340, 2009.
41. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol 27: 1-7, 2006.
42. Petrovic N, Schacke W, Shapiro LH. CD13/aminopeptidase N in tumor growth and angiogenesis. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/ Plenum. 2004. p. 179-200.
43. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci 99: 1188-1194, 2008.
44. Ramírez-Expósito MJ, Carrera-González Mdel P, Mayas MD, Dueñas B, Martínez-Ferrol J, Martínez-Martos JM. Neoadjuvant chemotherapy modifies serum angiotensinase activities in women with breast cancer. Maturitas 72: 79-83, 2012.
45. Re RN. Noncanonical intracrine action. J Am Soc Hypertens 5: 435-448, 2011.
46. Re RN, Cook JL. An intracrine view of angiogenesis. Bioessays 28: 943-953, 2006.
47. Re RN, Cook JL. The intracrine hypothesis: an update. Regul Pept 133: 1-9, 2006.
48. Sakai I, Miyake H, Takenaka A, Fujisawa M. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104: 942-946, 2009.
49. Scornik OA, Botbol V. Effects on mammals of the aminopeptidase inhibitor bestatine. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum, 2004, p. 127-143.
50. Shibata K, Kikkawa F, Suzuki Y, Mizokami Y, Kajiyama H, Ino K, Nomura S, Nagasaka T, Mizutani S. Expression of placental leucine aminopeptidase is associated with a poor outcome in endometrial endometrioid carcinoma. Oncology 66: 288-295, 2004.
51. Shrimpton CN, Smith AI, Lew RA. Soluble metallopeptidases and neuroendocrine signaling. Endocrine Rev 23: 647-664, 2002.
52. Siegel R, Naishadham MA, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
53. Silveira PF, Irazusta J, Gil J, Agirregoitia N, Casis L. Interactions among challenges of hydromineral balance, angiotensin-converting enzyme, and cystine aminopeptidase. Peptides 22: 2137-2144, 2001.
54. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 302: F1351-F1361, 2012.
55. Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 12: 3971-3978, 2006.
56. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 135: 92-109, 2011.
57. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 8: 3747-3754, 2002.
58. Varona A, Blanco L, López JI, Gil J, Agirregoitia E, Irazusta J, Larrinaga G. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 292: F780-F788, 2007.
59. Varona A, Blanco L, Perez I, Gil J, Irazusta J, López JI, Candenas ML, Pinto FM, Larrinaga G. Expression and activity profiles of DPPIV/ CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 10: 193, 2010.
60. Wickström M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102: 501-508, 2011.
61. Yoshimoto T, Ogita K, Walter R, Koida M, Tsuru D. Post-proline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochim Biophys Acta 569: 184-192, 1979.
62. Yue QX, Cao ZW, Guan SH, Liu XH, Tao L, Wu WY, Li YX, Yang PY, Liu X, Guo DA. Proteomics characterization of the cytotoxicity mechanism of ganoderic acid D and computer-automated estimation of the possible drug target network. Mol Cell Proteomics 7: 949-961, 2008.
63. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 38: 351-376, 2002.
64. Zhang MZ, Qiao YH, Suo ZH. Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma. Zhonghua Zhong Liu Za Zhi 30: 848-852, 2008.
65. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med 25: 247-257, 2005.